Хронический миелолейкоз — до и после иматиниба (часть III)
Аннотация
Появление иматиниба (ИМ) кардинально изменило подходы к терапии хронического миелолейкоза (ХМЛ). Ингибиторы тирозинкиназ (ИТК) второго поколения — нилотиниб и дазатиниб, разработанные вскоре после ИМ, – уже нашли широкое применение у больных ХМЛ с неэффективностью или непереносимостью ИМ. Наличие в рутинной медицинской практике трех ИТК, аллогенная трансплантация гемопоэтических стволовых клеток (алло-ТГСК), а также разработка большого числа новых препаратов делают вполне реальным излечение всех пациентов с ХМЛ, до недавнего времени считавшимся фатальным заболеванием. В первых 2 частях статьи содержались общие сведения о ХМЛ, подробно были освещены вопросы по алло-ТГСК, приводились данные по механизму действия ИТК и их безопасности. Последняя часть статьи посвящена эффективности терапии ИТК и современным рекомендациям по ведению пациентов с ХМЛ в разных фазах болезни.
Об авторах
Е. Г. Ломаиа
ФГУ Федеральный центр сердца, крови и эндокринологии им. В. А. Алмазова
Россия
Россия
Санкт-Петербург
М. Ю. Коноплева
ФГУ Федеральный центр сердца, крови и эндокринологии им. В. А. Алмазова
Россия
Россия
Санкт-Петербург
Е Г. Романова
ФГУ Федеральный центр сердца, крови и эндокринологии им. В. А. Алмазова
Россия
Россия
Екатерина Геннадьевна Романова
Санкт-Петербург
А. Ю. Зарицкий
ФГУ Федеральный центр сердца, крови и эндокринологии им. В. А. Алмазова
Россия
Россия
Санкт-Петербург
Список литературы
1. Kantarjian H. M., Talpaz M., O'Brien S. et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002; 8 (7): 2177—87.
2. Туркина А. Г Эффективность терапии иматиниб мезилатом (Гливеком) в хронической фазе миелолейкоза / А. Г. Туркина [и др.] // Тер арх. – 2003. – 75: 62—7.
3. Kantarjian H. M., Cortes J. E., O'Brien S. et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome - positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 2004; 104: 1979—88.
4. Kantarjian H. M., O'Brien S., Cortes J. E. et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 2003; 98: 2636—42.
5. Druker B. J., Talpaz M., Resta D. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031—7.
6. Kantarjian H., O'Brien S., Cortes J. et al. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer 2003; 98: 1430—7.
7. Зарицкий А. Ю. Факторы прогноза при терапии препаратом Иматиниба мезилатом у больных в хронической фазе Ph-позитивного хронического миелолейкоза: данные многоцентрового нерандомизированного исследования в России / А. Ю. Зарицкий [и др.] // Тер арх. – 2007. – 79 (8): 17—22.
8. Abdulkadirov K., Lomaia E., Shuvaev V. et al. 6-year experience of treatment by Imatinib in CML CP patients in 6 million population region of Russia (Saint-Petersburg and Leningrad region) with impact on time and kind of pretreatment. Blood 2009; 114 (22): abstr 4278.
9. Hensley M. L., Ford J. M. Imatinib treatment: specific issues related to safety, fertility and pregnancy. Semin Hematol 2003; 40 (2): Suppl 2: 21—5.
10. Shepherd P. C., Richards S., Allen N. C. Severe cytopenia with sequential use of busulphan and interferon alpha in chronic myeloid leukemia. Br J Haematol 1994; 86: 92—6.
11. Palandri F., Iacobucci I., Martinelli G. et al. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia positive chronic myeloid leukemia: The GIMEMA Working Party on CML. J Clin Oncol 2008; 26: 106—11.
12. Cortes J., Giles F., O'Brien S. et al. Result of high-dose imatinibe mesilate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferone-alfa. Blood 2003; 102 (1): 83—6.
13. Jabbour E., Kantarjian H., Jones D. et al. Imatinib mesylate dose escalation is associated with durable response in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009; 113 (10): 2154—60.
14. Druker B. J., Guilhot F., O'Brien S. et al. IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355 (23): 2408—17.
15. Deininger M., O'Brien S., Guilhot F. et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly тdiagnosed chronic myeloid leukemia in chronic phase treated with imatinib. Blood 2009; 114 (22): 462:abstr 1126.
16. Hochhaus A., Drucker B. J., Larson R. A. 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2007; 110: abstr 25.
17. O'Brien S. G., Guilhot F., Larson R. A. et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008; 112: abstr 186.
18. Kantarjian H. M., Larson R. A., Guilhot F. et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009; 115 (3): 551—60.
19. Kantarjian H. M., Talpaz M., O'Brien S. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873—8.
20. Baccarani M., Druker B., Cortes J. et al. 24 months update of the TOPS study: a phase III, randomized, open-label study of 400mg/d vs 800mg/d of imatinib mesylate in patients with newly diagnosed, previously untreted chronic myeloid leukemia in chronic phase. Blood 2009; 114 (22): 142—3:abstr 337.
21. Baccarani M., Rosti G., Castagnetti F. et al. A comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukemia: a European LeukemiaNet study. Blood 2009; 113 (19): 4497—504.
22. Palandri F., Castagnetti F., Iacobucci I. et al. The combination of interferon-alpha with imatinib in early chronic phase chronic myeloid leukemia patients induced a significant improvement of the molecular responses in the first two years of treatment: results from three studies from GIMEMA CML Working Party. Blood 2009; 114 (22): 862:abstr 2192.
23. Guilhot F., Preudhomme C., Guilhot J. et al. Significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon-alpha in combination with imatinib form the treatment of newly diagnosed chronic phase chronic myeloid leukemia patients: conformatory results at 18 months of part 1 of the Spirit phase III randomized trial of the French CML Group. Blood 2009; 114 (22): 144:abstr 340.
24. Talpaz M., Silve R. T., Druker B. J. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928—37.
25. Palandri F., Castagnetti F., Alimena G. et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after 7-year follow-up. Haematologica 2009; 94 (2): 205—12.
26. Piazza R. G., Magistroni V., Franceschino A. et al. The achievement of durable complete cytogenetic remission in late chronic phase and accelerated phase patients with CML treated with imatinib mesylate predicts for prolonged response at 6 years. Blood cells, molecules and diseases; June 2006; online at www.sciencedirect.com
27. Silver R. T., Talpaz M., Sawyers C. L. et al. Four years of follow-up of 1027 patients with late chronic phase, accelerated phase or blast crisis chronic myeloid leukemia treated with imatinib mesilate in three large phase II trials. Blood 2004; 16 (104), 11 (Pt1): 11a.
28. Palandri F., Castagnetti F., Testoni N. et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica 2008; 93 (12): 1792—6.
29. Kantarjian H. M., O'Brien S., Talpaz M. et al. Outcome of patients with philadelphia positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007; 109: 1556—60.
30. Weisser M., Schleuning M., Haferlach C. et al. Allogeneic stem cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymph 2007; 48 (2): 295—301.
31. Kantarjian H., Giles F., Gattermann N. et al. Nilotinib is highly effective and safe in chronic myelogenous leukemia patients with imatinib resistance and intolerance. Blood 2007; 110 (11): abstr 735.
32. Kantarjian H. M., Giles F., Bhalla K. et al. Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety and long-term outcomes. Blood 2009; 114 (22); 464. Abstr 1129.
33. Giles F., le Coutre F., Bhalla K. N. et al. Efficacy and tolerability of nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP). Who failed prior imatinib and dasatinib therapy: Updated results of a phase 2 study. ASH 2008; abstr 3234.
34. Jabbour E., Kantarjian H., Giles F. et al. Treatment with nilotinib for patients with chronic myeloid leukemia who failed prior therapy with imatinib and dasatinib. Blood 2006; 108: 7038.
35. Breccia M., Cannella L., Nanni M. et al. Nilotinib can override dasatinib resistance in chronic myeloied leukemia patients with secondary resistance to imatinib first-line therapy. Acta Hematol 2007; 118: 162—4.
36. Lipton J., le Coutre F., Wang J. et al. Nilotinib in elderly chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: efficacy and safety analysis. ASH 2008; abstr 3233.
37. Cortes J., O'Brien S., Ferrajoli A. et al. Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood ASH 2008; abstr 446.
38. Saglio G., Kim D.-W., Issaragrisik S. et al. Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the International Randomized Phase III ENESTnd Trial. Blood; 2009; 114 (22); abstr LBA-1.
39. Le Coutre P., Giles F., Apperley J. et al. Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia patients with imatinib resistance and intolerance. Blood 2007; 110 (11): abstr 471.
40. Le Coutre P., Ottmann O. G., Giles F. et al. Nilotinib (formely AMN107), highly selective BCR-ABL tytosine kinase inhibitor, in active in patients with imatinib resistant or intolerant accelerated phase chronic myelogenous leukemia. Blood 2008; 111: 1834—9.
41. Hochhaus A., Giles F., Apperlay J. et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study. Haematologica 2009; 256: abstr 631.
42. Martinelli G., Kim D. W., Saglio G. et al. Response to nilotinib is similar in imatinib resistant chronic myeloid leukemia patients in accelerated phase with and without BCR-ABL mutations exept E255K/V, Y253H and F359C/V. Haematologica 2009; 258: abstr 635.
43. Giles F., Kantarjian H. M., Wunderle L. et al. Nilotinib in chronic myelogenous leukemia in blast crisis (CML-BC) patients with imatinib resistance or intolerance: update phase II results. J Clin Oncol 2008; 26: 7012.
44. O'Hare T., Walters D. K., Stoffregen E. P. et al. In vitro activity of bcr-abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant abl-kinase domain mutants. Cancer Res 2005; 65: 4500—5.
45. Talpaz M., Shah N. P., Kantarjian H. M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531—41.
46. Hochhaus A., Baccarani M., Deininger M. et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22 (6): 1200—6.
47. Hochhaus A., Kantarjian H., Baccarani M. et al. Dasatinib induces notable hematologic and cytogenetic responsec in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303—9.
48. Kantarjian H., Pasquini R., Hamerschlak N. et al. Dasatinib or high dose imatinib for chronic phase chronic myeloid leukemia after failure of first line imatinib: a randomized phase 2 trial. Blood 2007; 109: 5143—50.
49. O'Brien S. G., Deininger M. W. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Sem Hematol 2003; 40 (2); Suppl 2: 26—30.
50. Shah N. P., Kantarjian H. M., Kim D. W. et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib resistant and intolerant chronic phase chronic myeloid leukemia. J Clin Oncol 2008; 26 (19): 3204—12.
51. Guilhot F., Apperley J., Kim D. W. et al. Dasatinib induces significant hematologic and cytogenetic responsec in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase. Blood 2007; 109 (10): 4143—50.
52. Guilhot F., Apperley J., Kim D. W. et al. Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up date from START-A (CA180-005). Blood 1007; 110 (11): abstr 470.
53. Cortes J., Rousselot P., Kim D. W. et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109 (8): 3207—13.
54. Cortes J., Borthakur G., O'Brien S. et al. Efficacy of dasatinib with presiously untreated chronic myelogenous leukemia in early chronic phase. Blood 2009; 114 (22): abstr 338.
55. Cortes J., O'Brien S., Pardanani A. et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood ASH 2008; abstr 182.
56. Kantarjian H. M. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 2008; 112: 837—45.
57. Huges T., Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukemia. Blood Rev 2006; 20 (1): 29—41.
58. Baccarani M., Saglio G., Goldman J. et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006; 108: 1809—20.
59. Kim D., Popradi G., Sriharsha L. et al. Significance of derivative chromosome 9 deletion on the clearence kinetics of bcrabl fusion transcripts, cytogenetic and molecular response, loss of response or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. Cancer 2008; 113: 772—82.
60. Marin D., Milojkovic D., Olavarria E. et al. European LeukemiaNet criteria for failure or suboptomal response reliable identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008; 112: 4437—44.
61. De Lavallade H., Apperley J., Khoroshad J. et al. Imatinib for newly diagnosed patients with chronic myeloid: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358—63.
62. Мартынкевич И. С. Клональная эволюция у пациентов с Ph-позитивным ХМЛ после терапии гливеком / И. С. Мартынкевич [и др.] // Вестн гематол. – 2007. – 3 (1): 30—4.
63. O'Dwyer M., Mauro M., Blasdel C. et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate (STI571). Blood 2004; 103 (2): 451—5.
64. Baccarani M., Cortes J., Pane F. et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27 (35): 6041—51.
65. Jabbour E., Cortes J. E., Kantarjian H. M. et al. Suboptimal response to or failure of imatinib treatment for chronic myelogenous leukemia: what is the optimal strategy? Mayo Clin Proc 2009; 84: 161—9.
66. Kantarjian H., Giles F., Gattermann N. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540—6.
67. Milojkovic D., Bua M., Apperley J. et al. Prediction of cytogenetic response to second generation TKI therapy in CML chronic phase patients who have failed imatinib therapy and early identification of factors that influence survival. Blood 2008; 112: abstr 332.
68. Alimena G., Breccia M., Latagliata R. et al. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. Cancer 2006; 107 (5): 1008—13.
69. Lahaye T., Riehm B., Berger U. et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005; 103 (8): 1659—69.
70. O'Brien S. G., Guilhot F., Larson R. A. et al. IRIS investigators. Imatinib com-pared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348 (11): 994—1004.
71. Nicolini F. E., Corm S., Le Q. H. et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French inter-group of CML (Fi(phi)-LMC GROUP). Leukemia 2006; 20 (6): 1061—6.
72. Soverini S., Martinelli G., Rosti G. et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23 (18): 4100—9.
73. Calabretta B., Perrotti D. The biology of CML blast crisis. Blood 2004; 103 (11): 4010—22.
74. Skorski T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 2002; 21 (56): 8591—604.
75. Koptyra M., Falinski R, Nowicki M. O. et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108 (1): 319—27.
76. Apperley J. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia, Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8 (12): 1116—28.
77. Willis S., Lange T., Demehri S. et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinibnaive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106 (6): 2128—37.
78. Jabbour E., Kantarjian H., Jones D. et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006; 20 (10): 1767—73.
79. Anand M., Khorashad J., Marin D. et al. Varying response to escalating the dose of imatinib in patients with CML who «acquire» a BCR-ABL M244V mutant allele. Blood 2006; 108 (8): 2881—2.
80. Hochhaus A., Druker B., Sawyers C. et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008; 112: abstr 3216.
81. Muller M. C., Cortes J., Kim D. W. et al. Dasatinib efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) and pre-existing BCR-ABL mutations. Blood 2008; 112; abstr 449.
82. Branford S., Rudzki Z., Walsh S. et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102 (1): 276—83.
83. Skorzski T. BCR-ABL, DNA damage and DNA repair: implications for new concepts of treatment. Leuk Lymph 2008; 49 (4): 610—4.
84. Nicolini F., Hayette S., Corm S. et al. Clinical outcome of 27 imatinib-resistant chronic myelogenous leukemia patients harboring a T315I bcr-abl mutation. Hematologica 2007; 92: 1238—41.
85. Miething C., Feihl S., Mugler C. et al. The bcr-abl mutations T315I and Y253H do not confer the growth advantage in the absence of imatinib. Leukemia 2006; 20: 650—7.
86. Kim S. H., Kim D., Kim D. W. et al. Analysis of bcr-abl-kinase domain mutations in Korean chronic myeloid leukemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. Hematol Oncol 2009; 27 (4): 190—7.
87. Горюнова Е. Н. Течение хронического миелолейкоза у пациента с панрезистентной мутацией Т315I в фазе акселерации. Всегда ли необходима аллогенная трансплантация костного мозга при мутации Т315I? / Е. Н. Горюнова [и др.] // Клин онкогематол. – 2009; 2 (1): 11—3.
88. Cortes J., O'Dwyer M. E. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004; 8 (3): 671—84.
89. Picard S., Titier K., Etienne G. et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496—9.
90. Gambacorti-Passerini C., Zucchetti M., Russo D. et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003; 9 (2): 625—32.
91. Mahon F. X., Belloc F., Lagarde V. et al. MDR-1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101 (6): 2368—73.
92. Crossman L. C., Druker B. J., Deininger M. W. et al. hOCT 1 and resistance to imatinib. Blood 2005; 106 (3): 1133—4.
93. Mattar M. Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase. Int J Hematol 2010; 91 (1): 104—6.
94. Asfour I. A., Elshazly S. A. Changing therapy from Glivec to a «copy» imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports. Cases J 2009; 2: 9342.
95. O'Hare T., Eide C. A., Deininger M. W. et al. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110 (7): 2242—9.
96. Soverini S., Gnani A., Colarossi S. et al. Philadelphia chromosome positive leukemia patients who harbor imatinib resistant mutations have a higher likeli-hood of developing additional mutations associated with resistance to novel tyrosine kinase inhibitors. Blood 2007; 110 (11): abstr 322.
97. Silver R. T., Peterson B. L., Szatrowski T. P. et al. Treatment of the chronic phase of chronic myeloid leukemia with an intermittemtn schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. Leuk Lymph 2003; 44 (1): 39—48.
98. Burchert A., Muller M. C., Kostrewa P. et al. Interferon Alpha 2a (IFN) maintenance therapy after imatinib plus IFN induction therapy in chronic myeloid leukemia induces stable long-term molecular remissions and is associated with increased proteinase-3 expression and the presence of PR1-specific T-cells. Blood 2009; 114:abstr 647.
99. Bocchia M., Korontsvit T., Xu Q. et al. BCR-ABL derived peptide vaccine in chronic myeloid leukemia patients with molecular minimal residual disease during imatinib:interim analysis of phase 2 multicenter GIMEMA CML working party trial. Blood 2009; 114 (22): abstr 648.
100. Abruzzese E., Trawinska M., Coletta A. et al. Peptide-vaccine treatment associated with therapy in patients with CML is able to induce immunologic, cytogenetic and molecular responses: single center experience with long-term follow up. Blood 2009; 114 (22): abstr 2185.
101. Cortes-Franco J., Parikh P., Wetzler M. et al. Safety and efficacy of subcutaneous-administered omacetaxine mepusuccinate in chronic myeloid leukemia patients who are resistant or intolerant to two or more tyrosine kinase ingibitors - results of a multicenter phase 2/3 study. Blood 2009; 114 (22): abstr 861.
102. Cortes-Franco J., Parikh P., Wetzler M. et al. Safety and efficacy of subcutaneous-administered omacetaxine mepecuccinate in imatinib-resistant chronic myeloid leukemia patients who harbor the bcr-abl T315I mutation - results of ongoing multicenter phase 2/3 study. Blood 2009; 114 (22): abstr 644.
103. Ayoubi M., Kantarjian H. M., Wierda W. et al. A phase 2 study of the combination of omacetaxine and imatinib in the treatment of patients with chronic myeloid leukemia in advanced stages or after failure to imatinib. Blood 2009; 114 (22): abstr 2193.
104. Minami Y., Lowell A. M., Borgman C. L. et al. Treatment with m-TOR ingibitor, everolimus (RAD001) overcomes resistance to imatinib in Ph-leukemia quiescent or T315I mutated cells. Blood 2009; 11 (22): abstr 3277.
105. Cortes J., Talpaz M., Deininger M. et al. A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutation. Blood 2009; 114 (22): abstr 643.
106. Cortes J., Bruemmendorf T., Kantarjian H. et al. Efficacy and safety among patients with chronic phase Ph + chronic myelogenous leukemia. Blood 2007; 110 (11): 225:abstr 733.
107. Keller G., Schafhausen P., Brümmendorf T. H. Bosutinib. Recent Results Cancer Res 2010; 184: 119—27.
108. Cortes-Franco J., Dombret H., Schafhausen P. et al. Danusertib Hydrochloride (PHA-739358), a multikinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia. Blood 2009; 114 (22): abstr 864.
109. Rousselot P., Huguet F., Rea D. et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109 (1): 58—60.
110. St Charles M., Bollu V., Hornyak E. et al. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. Blood 2009; 114 (22): abstr 2209.
Рецензия
Для цитирования:
Ломаиа Е.Г., Коноплева М.Ю., Романова Е.Г., Зарицкий А.Ю. Хронический миелолейкоз — до и после иматиниба (часть III). Онкогематология. 2010;(1):5-20.
For citation:
Lomaia E.G., Konopleva M.Yu., Romanova E.G., Zaritzkiy A.Yu. Chronic myeloid leukemia — before and after imatinib (Third part). Oncohematology. 2010;(1):5-20. (In Russ.)
Просмотров:
8938
Послать статью по эл. почте 